OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 9,673 Shares

OmniAb, Inc. (NASDAQ:OABI) insider Charles Berkman sold 9,673 shares of OmniAb stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $16,540.83. Following the completion of the sale, the insider owned 392,700 shares of the company’s stock, valued at approximately $671,517. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

OmniAb Price Performance

NASDAQ:OABI remained flat at $1.71 during trading hours on Wednesday. The company had a trading volume of 342,206 shares, compared to its average volume of 375,697. The firm has a market capitalization of $246.17 million, a P/E ratio of -2.95 and a beta of 0.13. OmniAb, Inc. has a 1-year low of $1.22 and a 1-year high of $4.02. The firm has a fifty day moving average of $1.89 and a 200 day moving average of $1.76.

Hedge Funds Weigh In On OmniAb

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its stake in shares of OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of OmniAb in the 1st quarter valued at $25,000. BNP Paribas Financial Markets boosted its holdings in shares of OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after acquiring an additional 10,438 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of OmniAb by 111.5% during the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after acquiring an additional 11,919 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in OmniAb by 96.6% during the 4th quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock worth $43,000 after acquiring an additional 11,369 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb News Summary

Here are the key news stories impacting OmniAb this week:

• Positive Sentiment: Institutional buying and concentrated ownership: several funds (Osaic, AQR, BNP Paribas, Cerity Partners, SG Americas) have recently increased or established stakes; institutional ownership is reported above 70%, which can support liquidity and longer-term stability. MarketBeat OABI page
• Neutral Sentiment: Analyst coverage is mixed: MarketBeat shows an average “Moderate Buy” rating and a mean price target near $6.67, but Weiss Ratings has a “sell (e+)” on the stock — a signal of divergent views that can keep trading range-bound. MarketBeat OABI page
• Neutral Sentiment: Key trading metrics: shares are being reported around $1.71 with a 50-day moving average (~$1.89) and 200-day (~$1.76); negative trailing P/E reflects current losses. These metrics frame risk/reward but do not convey near-term directional catalysts. MarketBeat OABI page
• Negative Sentiment: CEO Matthew W. Foehr sold shares on Feb. 17–18 (totaling 51,597 shares across two filings), reducing his stake modestly; filings: Feb. 18 sale. CEO Feb 18 Form 4 and Feb. 17 sale. CEO Feb 17 Form 4
• Negative Sentiment: CFO Kurt A. Gustafson sold shares on Feb. 17–18 (totaling 16,129 shares across two filings), trimming his holding by a few percent; filings: Feb. 18. CFO Feb 18 Form 4 and Feb. 17. CFO Feb 17 Form 4
• Negative Sentiment: Director Charles S. Berkman sold shares on Feb. 17–18 (totaling 16,663 shares across two filings), reducing his stake by a few percent; filings: Feb. 18. Director Feb 18 Form 4 and Feb. 17. Director Feb 17 Form 4

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, OmniAb currently has an average rating of “Moderate Buy” and a consensus price target of $6.67.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.